NCT02738866 Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02690480 Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer Status UNKNOWN Phase PHASE2
NCT02684032 A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer Status COMPLETED Phase PHASE1
NCT02675231 A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT02657343 An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Status COMPLETED Phase PHASE1/PHASE2
NCT02640755 Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase Status COMPLETED Phase PHASE1
NCT02632045 Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer Status COMPLETED Phase PHASE2
NCT02599714 Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer Status COMPLETED Phase PHASE1
NCT02569801 A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy Status TERMINATED Phase PHASE2
NCT02549430 To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy Status COMPLETED Phase PHASE2
NCT02540330 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant Status TERMINATED Phase PHASE2
NCT02536742 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT02530424 "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " Status COMPLETED Phase PHASE2
NCT02530411 Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer Status UNKNOWN Phase PHASE2
NCT02491983 Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer Status COMPLETED Phase PHASE2
NCT02476786 Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Status RECRUITING Phase PHASE2
NCT02447328 A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Status COMPLETED Phase PHASE4
NCT02437318 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Status COMPLETED Phase PHASE3
NCT02422615 Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Status COMPLETED Phase PHASE3
NCT02404051 Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer Status UNKNOWN Phase PHASE3